Norovirus Infections Clinical Trial
Official title:
Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine(Hansenula Polymorpha) in Healthy People Aged Aged From 6 Months to 59 Years
Phase II clinical study will explore dose and safety, immunogenicity in 4 age groups, including 18-59 years old group, 6-17 years old group, 3-5 years old group, 6-35 months old group, with a total of 1716 subjects.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02371538 -
Human Breastmilk in Young Children With Norovirus Infection of the Gut
|
N/A | |
| Completed |
NCT04188691 -
A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine
|
Phase 1 | |
| Not yet recruiting |
NCT05916326 -
Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha)
|
Phase 3 | |
| Completed |
NCT05212168 -
Norovirus Challenge Study
|
Phase 1/Phase 2 | |
| Completed |
NCT05213728 -
A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers
|
Phase 1 | |
| Completed |
NCT06211621 -
Admission Pattern Among Children With Gastro-intestinal Infections Before and During the Covid-19 Pandemic
|
||
| Active, not recruiting |
NCT05626803 -
A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
|
Phase 2 | |
| Completed |
NCT01435811 -
Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1)
|
Phase 1 | |
| Completed |
NCT04875676 -
Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines
|
Phase 1/Phase 2 | |
| Completed |
NCT04854746 -
Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine
|
Phase 1 |